Positive results for PMDD study

Umecrine Mood announces positive results from study with UC1010 in PMDD

Understanding of predictive models in oncology

Industry leaders will discuss use of Patient-Derived Xenograft models to help accelerate oncology drug discovery

Drug Discovery 2014

ELRIG Announces Drug Discovery 2014 Programme and Pre-Conference SLAS Short Courses

Encouraging findings for Parkinson’s disease vaccine

First clinical data of therapeutic Parkinson’s disease vaccine encourages continued development

Securing performance in drug delivery devices

Polymers in Drug Delivery Devices 2014 conference takes place September 16-17 at the Hilton Philadelphia City Avenue in Philadelphia, PA, USA

Silver lining found for making new drugs

Chemical to aid drug manufacturing processes, making it more environmentally-friendly and easier to scale up for industry

High payload targeted drug delivery

New targeted nanoparticles are expected to dramatically improve the effectiveness of both diagnosis and treatment of diseases and reduce dangerous or unpleasant side effects

Anti-vWF nanobody, caplacizumab, achieves proof-of-concept

Phase II TITAN study produces positive results for Abylnx’s anti-vWF nanobody

Novel strategies for combining drug therapy with irradiation

Could deliver new hope for overcoming resistance to oncology therapeutics

Oral agent normalises glucose tolerance and insulin sensitivity

Imeglimin induces glucose-stimulated insulin secretion by improving beta cell glucose sensitivity in Type 2 diabetic patients

New screening library designed to increase hit probability

Delivering highly diverse coverage of drug-like chemical space in a single library

Additional data on ALX-0061 nanobody to be presented

Ablynx will present additional data on ALX-0061, the anti-IL-6R nanobody, at rheumatology congress

Identifying novel hits against a disease-relevant protease

Beactica initiates drug discovery collaboration with Medivir

First results confirm drug discovery potential of the European Lead Factory

European Lead Factory is a novel, open-innovation platform for drug discovery, managed by an international consortium of 30 partners

Malaria trial results presented

Results from exploratory Phase I/II clinical trial in uncomplicated malaria

Optimise drug screening processes

Crown Bioscience to showcase progression in human surrogate trials at the 50th ASCO Annual Meeting

Second technology deal successfully closed

Sygnis announces Double Switch technology patent deal with Systasy Bioscience

Double Switch technology patent deal

SYGNIS' proprietary Double Switch technology addresses key needs in proteomics and drug development

Brain atrophy slowed in patients treated with Lemtrada

Slowing of brain atrophy and reductions in new MS lesions in patients treated with Lemtrada



Twitter Icon © Setform Limited